As shown in Figure 1, high PTEN levels (score 2–3) were detectable in 26% of disease free, 30% of relapsed groups, and only 16% of metastatic diseases, whereas 84% of the metastatic patients presented null or low (score 1) PTEN expression. Here, PTEN is linked to metastatic neoplasm.